Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients will be ascertained in Finland from previous health surveys and hospital discharge records. Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on family members and blood drawn for DNA isolation. Covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis.
The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as NIDDM and intermediate traits like IR.
Non-Insulin Dependent Diabetes Mellitus
|Official Title:||Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus|
|Study Start Date:||March 1995|
The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to
identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits. This
involves the phenotyping and DNA analysis of thousands of individuals living in Finland, utilizing a study design that was originally based on affected sib pairs. The majority of these samples have already been subjected to a genome scan using microsatellite markers and the original FUSION samples plus thousands of other cases and controls have been subjected to genome-wide association (GWA) analysis. More recently, the opportunity provided by the lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of these individuals.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00339885
|Contact: Ann C. M. Smith||(301) email@example.com|
|Contact: Lori Bonnycastle, Ph.D.||(301) firstname.lastname@example.org|
|United States, District of Columbia|
|Howard University Hospital||Recruiting|
|Washington, District of Columbia, United States, 20060|
|National Public Health Institute||Recruiting|
|Helsinki University Hospital District||Recruiting|
|University of Kuopio||Recruiting|
|Research Ethics Committee of Hospital District of Northern Savo||Recruiting|
|HUNT Research Center and Biobank||Recruiting|
|University of Science and Technology (NTNU)||Recruiting|
|Principal Investigator:||Lori Bonnycastle, Ph.D.||National Human Genome Research Institute (NHGRI)|